Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Silarus Therapeutics
c/o COI Pharmaceuticals
11099 North Torrey Pines Road, Suite 290
La Jolla, CA 92037
http://www.coipharma.com/portfolio/silarus/

Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Erythroferrone is a recently-discovered hormone that regulates the iron supply for red blood cell production. Iron deficiency, also known as anemia, is a condition in which blood does not contain the normal amount of red blood cells or lacks the proper amount of hemoglobin. This, in turn, lowers the amount of oxygen-rich blood in circulation, causing shortness of breath, dizziness or headaches. Iron overload is a condition in which too much iron builds up in the body, causing organ poisoning or failure. Silarus was founded based on intellectual property in-licensed from the University of California, Los Angeles, that was discovered by investigators Tomas Ganz, M.D., Ph.D., Professor of Medicine, Department of Pathology and Laboratory Medicine and Elizabeta Nemeth, Ph.D., Professor of Medicine, Division of Pulmonary and Critical Care, both of the UCLA David Geffen School of Medicine.

Key Contact
Name
Jay Lichter
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
09/22/14 $10,000,000 Series A Avalon Ventures
GlaxoSmithKline
undisclosed